My ePortfolio Register   

AACR 2017 /
Long-term clinical outcomes and analyses of atezolizumab for mTNBC

1st - 5th Apr 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.04.17
Views: 1116

Prof Peter Schmid - Barts Cancer Institute, London, UK

Prof Schmid presents research from a phase Ia expansion study at AACR 2017, evaluating responses to atezolizumab in patients with metastatic triple negative breast cancer.

Slides from this presentation are available here.

Prof Schmid discussed these results further with ecancer here.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence